| Identification | Back Directory | [Name]
5,8-dioxo-6-(pyridin-3-ylamino)naphthalene-1-sulfonamide | [CAS]
1436382-03-4 | [Synonyms]
5,8-dioxo-6-(pyridin-3-ylamino)naphthalene-1-sulfonamide | [Molecular Formula]
C15H11N3O4S | [MDL Number]
MFCD28386216 | [MOL File]
1436382-03-4.mol | [Molecular Weight]
329.33 |
| Chemical Properties | Back Directory | [Boiling point ]
635.6±65.0 °C(Predicted) | [density ]
1.585±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [pka]
9.15±0.20(Predicted) |
| Hazard Information | Back Directory | [Description]
LY5 is a STAT3 inhibitor. It acts by inhibiting cell viability, cell migration, and angiogenesis in medulloblastoma cells. | [Uses]
LY5 is a STAT3 inhibitor with an IC50 value of 0.5 μM. LY5 induces apoptosis and inhibits STAT3 phosphorylation. LY5 shows antitumor activity in vivo, it can be used for the research of cancer[1]. | [in vivo]
LY5 (5 mg/kg; i.p. once daily for 21 days) inhibits breast tumor growth in vivo[1]. | Animal Model: | Nude mice with MDA-MB-231 cancer cells injection[1] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection; 5 mg/kg; once daily; for 21 days | | Result: | Suppressed tumor growth and significantly reduced the tumor sizes.
|
| [storage]
Store at -20°C | [References]
[1] Yu W, et al. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. J Med Chem. 2013 Jun 13;56(11):4402-12. DOI:10.1021/jm400080c |
|
|